^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Aromatase inhibitor

    Related drugs:
    2d
    Comparison of frozen embryo transfer outcomes in hormonal vs. mild stimulation protocols in polycystic ovary syndrome women: A randomized controlled trial. (PubMed, Int J Reprod Biomed)
    In HRT, oral estradiol followed by injectable progesterone was used; in MOS, letrozole +  follicle-stimulating hormone stimulation continued until follicle    17 mm and endometrium     7.5 mm, then human chorionic gonadotropin was given. However, the number of clinical pregnancies (p = 0.045) and the number of successful pregnancies (p = 0.049) were significantly higher in the MOS group compared to the HRT group. This study showed that MOS achieved higher clinical and successful pregnancy rates than HRT in women with PCOS.
    Journal
    |
    DKK1 (dickkopf WNT signaling pathway inhibitor 1) • LIFR (LIF Receptor Subunit Alpha) • LIF (LIF Interleukin 6 Family Cytokine)
    |
    letrozole
    2d
    Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
    P3, N=5018, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2032 --> Jan 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    2d
    BabyTears: Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer. (clinicaltrials.gov)
    P2, N=95, Recruiting, Andrea DeCensi | N=70 --> 95
    Enrollment change
    |
    ER (Estrogen receptor) • ATM (ATM serine/threonine kinase) • CHEK2 (Checkpoint kinase 2) • IGFBP3 (Insulin-like growth factor binding protein 3)
    |
    tamoxifen • exemestane
    7d
    FALCON: A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (clinicaltrials.gov)
    P3, N=462, Completed, AstraZeneca | Trial completion date: Aug 2027 --> Jan 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    fulvestrant • anastrozole
    11d
    FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles (clinicaltrials.gov)
    P=N/A, N=120, Not yet recruiting, University of Novi Sad
    New trial
    |
    letrozole
    12d
    Adebrelimab in combination with dalpiciclib and endocrine therapy as neoadjuvant treatment for HR+/HER2- early breast cancer: an exploratory study. (PubMed, Int J Surg)
    This triplet regimen demonstrated modest clinical activity in HR+/HER2- early BC, with the safety profile of this regimen remains a concern and warrants particular attention in clinical practice.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    letrozole • AiRuiKang (dalpiciclib) • AiRuiLi (adebrelimab)
    14d
    Spatially Resolved Transcriptomics Identifies Tumor-Stroma-Immune Networks and Therapeutic Targets in Endocrine-Resistant Advanced Breast Cancer Treated with Everolimus+Letrozole: Insights from the MIRACLE Trial. (PubMed, Cancer Lett)
    This finding suggests that tasquinimod, an S100A9 inhibitor, could be a viable therapeutic option. Furthermore, the interaction between MMP11 and COL16A1 in stroma-rich regions suggests that cancer-associated fibroblasts may contribute to improved outcomes. Our study underscores the critical role of spatial gene expression analysis in elucidating the tumor microenvironment and its impact on prognosis in patients undergoing E+L treatment, thereby opening new avenues for targeted interventions.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • S100A9 (S100 Calcium Binding Protein A9) • MMP11 (Matrix Metallopeptidase 11) • FKBP5 (FKBP Prolyl Isomerase 5) • SERPINA1 (Serpin Family A Member 1)
    |
    HR positive • HER-2 amplification + HR-positive
    |
    everolimus • letrozole • tasquinimod (ABR-215050)
    16d
    Safe use of ribociclib in a patient with HR+/HER2- metastatic breast cancer receiving chronic hemodialysis. (PubMed, J Oncol Pharm Pract)
    She received ribociclib with a reduced dose due to haematological toxicity, as well as letrozole and denosumab due to bone metastasis. Ribociclib was administered safely and effectively for nine months.DiscussionWe presented our experience of using ribociclib in a patient with metastatic breast cancer who was receiving hemodialysis. Ribociclib was administered safely, and a response to the treatment was achieved.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Kisqali (ribociclib) • letrozole • Prolia (denosumab)
    23d
    CYP3A4-Mediated Metabolism and Drug-Drug Interaction Potential of Abemaciclib and Letrozole In Vitro. (PubMed, Chem Biodivers)
    Additionally, abemaciclib metabolites further inhibited CYP3A4, showing a potential for pharmacokinetic interactions when the drugs are used together. This study highlights significant interactions between abemaciclib and letrozole, particularly their combined inhibitory effects on CYP3A4.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Verzenio (abemaciclib) • letrozole
    24d
    Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients (clinicaltrials.gov)
    P2/3, N=119, Completed, Tianjin Medical University Cancer Institute and Hospital | Recruiting --> Completed | Trial completion date: Sep 2026 --> Sep 2025
    Trial completion • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 expression
    |
    cyclophosphamide • epirubicin • exemestane • AiRuiKang (dalpiciclib) • goserelin acetate
    24d
    SIE-1: A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer (clinicaltrials.gov)
    P1, N=120, Not yet recruiting, Rovi Pharmaceuticals Laboratories
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    letrozole
    26d
    Impact of Treatment Related Neutropenia on Response to Palbociclib in Metastatic Hormone Positive, her2neu Negative Breast Cancer. (PubMed, Asian Pac J Cancer Prev)
    Neutropenia induced by palbociclib and subsequent dose reduction did not impact the disease outcome.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK6 (Cyclin-dependent kinase 6)
    |
    HR positive • HER-2 negative
    |
    Ibrance (palbociclib) • fulvestrant • letrozole